Clinical trials: Obsessive-compulsive Disorder (OCD)
Obsessive Compulsive Disorder
Duloxetine for the Treatment of Obsessive Compulsive Disorder (OCD)
The purpose of this study is to assess the efficacy of Duloxetine in the treatment of obsessive compulsive disorder.
- Trial name
- FIJ-MC-1003 (NCT00464698)
- Testing
- Duloxetine
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Massachusetts General Hospital
Obsessive-Compulsive Disorder
Extending Ketamine's Effects in OCD With Exposure and Response Prevention (EX/RP)
This study investigates if a single dose of IV Ketamine can rapidly improve Obsessive-Compulsive Disorder (OCD) symptoms and whether these effect can be maintained with a condensed course of a type of Cognitive Behavioral Therapy…
- Trial name
- NCT02062658
- Testing
- Ketamine, Exposure and Response Prevention
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- New York State Psychiatric Institute
Cognitive Behavioral Therapy, Autism Spectrum Disorder
Parent-Led Cognitive-Behavioral Teletherapy for Anxiety in Youth With ASD
This study implements an anxiety-focused, parent-led, therapist-assisted cognitive behavioral teletherapy for parents of youth with ASD and anxiety.
- Conditions
- Cognitive Behavioral Therapy, Autism Spectrum Disorder, Anxiety Disorders, Obsessive-Compulsive Disorder
- Trial name
- NCT04111874
- Testing
- Cognitive Behavioral Teletherapy LTA, Cognitive Behavioral Teletherapy STA
- Where
- United States
- Volunteers
- 87 people
- Sponsor
- Baylor College of Medicine
Obsessive Compulsive Disorder
D-Cycloserine Augmentation to CBT With Exposure and Response Prevention in Adults and Adolescents With OCD
This is a single site, open-label, feasibility study of cognitive behavioral therapy with exposure and response prevention (CBT/ERP) adding the augmentation of D-cycloserine (DCS) for adolescents ages 12-17 with Obsessive…
- Trial name
- NCT01172873
- Testing
- D-cycloserine, Exposure and Response Prevention (EX/RP)
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- New York State Psychiatric Institute